Quest Diagnostics (DGX) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenues reached $2.40 billion, up 2.5% year-over-year, with base business revenue growth of nearly 4%, driven by new physician and hospital customers, favorable test mix, and strong healthcare utilization.

• Announced and completed multiple acquisitions, including LifeLabs in Canada, Allina Health, OhioHealth, Lenco Diagnostic Laboratories, and PathAI Diagnostics, expanding presence in strategic markets and advanced diagnostics.

• Productivity and profitability improved through automation, AI, and the Invigorate program, enhancing service quality and efficiency.

• Net income attributable to Quest Diagnostics was $229 million for Q2 2024, down 2.4% year-over-year; reported diluted EPS was $2.03, compared to $2.05 in Q2 2023.

• Ongoing cost-saving initiatives and operational improvements offset inflationary pressures.

Financial highlights

• Q2 consolidated revenues reached $2.4 billion, up 2.5% year-over-year; base business revenues grew up to 4.2%.

• Diagnostic Information Services (DIS) revenues increased 2.8% year-over-year; clinical base business revenues up 5.1%.

• Adjusted operating income was $398 million (16.6% of revenues), up from $389 million (16.7%) last year; operating income for Q2 was $355 million.

• Adjusted EPS was $2.35, up from $2.30; reported EPS was $2.03, slightly down from $2.05 year-over-year.

• Cash from operations year-to-date was $514 million, down from $538 million last year; Q2 cash from operations was $360 million.

Outlook and guidance

• 2024 revenue guidance raised to $9.5–$9.58 billion; adjusted EPS expected at $8.80–$9.00; reported EPS guidance is $7.57–$7.77.

• Cash from operations projected at $1.3 billion; capital expenditures at $420 million.

• LifeLabs acquisition not included in 2024 guidance; expected to add ~$710 million annual revenue and $0.10–$0.15 accretion to adjusted EPS in first year post-close.

• Operating margin expected to expand for the full year, driven by volume growth and productivity.

• Guidance reflects $0.06–$0.08 Q3 headwind from recent IT outage and Hurricane Beryl.